Descartes-08 Consolidation Treatment in Patients With High-Risk Multiple

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT06205823` - Compare Clinical Outcomes Between Advanced Immunotherapy and Classical Immunochemotherapy in RRMM
Recruiting	`NCT04782687` - Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma	Phase 2
Active, not recruiting	`NCT05889221` - Multicenter Phase 2 Study of Subcutaneous Isatuximab Plus Bortezomib, Lenalidomide and Dexamethasone in the Treatment of Newly Diagnosed Transplant Ineligible Multiple Myeloma	N/A
Recruiting	`NCT03891914` - Prospective Comparison of 18F-choline PET/CT and 18F-FDG PET/CT in the Initial Work-up of Multiple Myeloma	Phase 3
Not yet recruiting	`NCT05944783` - Bioequivalence Studies of Dasatinib 100 mg	Phase 4
Recruiting	`NCT04268199` - A Multicentre, Non-Blinded Study Exploring Self-Administration of Chemotherapy in the Home Environment	Phase 2
Not yet recruiting	`NCT06133426` - Evaluation of the Role of Connected Scales in the Therapeutic Care of Hematology Patients	N/A
Completed	`NCT05887206` - Corneal Toxicity in Patients Treated by Belantamab Mafodotin
Completed	`NCT04065789` - Carfilzomib in Combination With Daratumumab, Lenalidomide and Dexamethasone in Transplant-ineligible NDMM Patients	Phase 2
Active, not recruiting	`NCT03089411` - Collection of Additional Data Followed the Study IFM 2013-04	N/A
Completed	`NCT04436029` - Descartes-11 Consolidation Treatment in Patients With High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy	Phase 2
Not yet recruiting	`NCT04364724` - CTFEA Myeloma Study
Recruiting	`NCT05932680` - Limited-duration Teclistamab	Phase 2
Not yet recruiting	`NCT06418750` - Evaluation of a Range of Dermo-cosmetic Products to Treat Skin and Nail Toxicity Linked to Bispecific Anti-GPRC5D Bispecific Antibodies in Multiple Myeloma Patients". Myeloma". Descriptive Pilot Study	N/A
Completed	`NCT04236063` - Rehabilitation Needs of the Malaysian Haematological Cancer Survivors
Terminated	`NCT04242121` - The Risk Stratification in Patients With Multiple Myeloma Based on Fluorescence Flow Cytometry Quantitative Determination of the Circulating Plasma Cells in the Peripheral Blood
Not yet recruiting	`NCT03607643` - A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies	Phase 1/Phase 2
Recruiting	`NCT05651932` - A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma	Phase 1
Not yet recruiting	`NCT06245629` - Bortezomib-bendamustine-melphalan vs Melphalan for Multiple Myeloma
Recruiting	`NCT03992170` - Study of Daratumumab in Multiple Myeloma (MM) Patients in >VGPR/MRD-positive	Phase 2

NCT number	NCT04816526
Study type	Interventional
Source	Cartesian Therapeutics
Contact	Adam Chowdhury, MD, MBA
Phone	3013488698
Email	adam.chowdhury@cartesiantx.com
Status	Recruiting
Phase	Phase 2
Start date	December 1, 2021
Completion date	March 15, 2025

Descartes-08 Consolidation Treatment in Patients With High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms